Posted by Michael Wonder on 21 Jan 2022
U.S. FDA approves second indication for Skyrizi (risankizumab-rzaa) to treat adults with active psoriatic arthritis
21 January 2022 - Skyrizi (risankizumab-rzaa) met the primary endpoint of ACR20 at week 24 in two pivotal studies, demonstrating significant improvement in joint symptoms, including swollen, tender and painful joints, compared to placebo.
AbbVie today announced the U.S. FDA has approved Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis, a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.
